Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: A prospective observational study

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Falck, Anna Karin ^a,b   Bendahl, Pär Ola ^a   Ingvar, Christian ^a,c   Isola, Jorma ^d   Jönsson, Per Ebbe ^b   Lindblom, Pia ^a,c   Lövgren, Kristina ^a   Rennstam, Karin ^a   Fernö, Mårten ^a   Rydén, Lisa ^a,c  

^a LUND UNIVERSITY   (Sweden)

^b HELSINGBORG HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF TAMPERE   (Finland)

Author keywords

Breast cancer; Cytokeratin positive cells; Disseminated tumour cells; Micrometastases; Prognosis

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BONE MARROW; BONE MARROW BIOPSY; BREAST CANCER; CANCER CYTODIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CIRCULATING TUMOR CELL; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROMETASTASIS; OBSERVATIONAL STUDY; PREDICTION; PRIMARY TUMOR; PROSPECTIVE STUDY; TUMOR VOLUME;

ADULT; AGED; BONE MARROW; BREAST NEOPLASMS; FEMALE; HUMANS; KERATINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM MICROMETASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; TUMOR BURDEN;

EID: 84865973943     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-403     Document Type: Article

References (31)

1. Sveriges kommuner och Landsting S Open comparisons of health care quality and efficiency: comparisons between counties in 2009 2009, www.skl.se/publikationer, Sveriges kommuner och Landsting S.
2. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20(8):1319-1329. 10.1093/annonc/mdp322, 2720818, 19535820.
3. Gebauer G, Fehm T, Lang N, Jager W. Tumor size, axillary lymph node status and steroid receptor expression in breast cancer: prognostic relevance 5 years after surgery. Breast Cancer Res Treat 2002, 75(2):167-173. 10.1023/A:1019601928290, 12243509.
4. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002, 347(8):567-575. 10.1056/NEJMoa020128, 12192016.
5. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, Kjaer M, Gadeberg CC, Mouridsen HT, Jensen MB, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997, 337(14):949-955. 10.1056/NEJM199710023371401, 9395428.
6. Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE, Wilson KS, Knowling MA, Coppin CM, Paradis M, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997, 337(14):956-962. 10.1056/NEJM199710023371402, 9309100.
7. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005, 353(8):793-802. 10.1056/NEJMoa050434, 16120859.
8. Fehm T, Krawczyk N, Solomayer EF, Becker-Pergola G, Durr-Storzer S, Neubauer H, Seeger H, Staebler A, Wallwiener D, Becker S. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res 2008, 10(5):R76. 10.1186/bcr2143, 2614509, 18793387.
9. Schwarzenbach H, Pantel K, Kemper B, Beeger C, Otterbach F, Kimmig R, Kasimir-Bauer S. Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer. Breast Cancer Res 2009, 11(5):R71. 10.1186/bcr2404, 2790848, 19772563.
10. Riethdorf S, Wikman H, Pantel K. Review: biological relevance of disseminated tumor cells in cancer patients. Int J Cancer 2008, 123(9):1991-2006. 10.1002/ijc.23825, 18712708.
11. Bidard FC, Vincent-Salomon A, Gomme S, Nos C, de Rycke Y, Thiery JP, Sigal-Zafrani B, Mignot L, Sastre-Garau X, Pierga JY. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin Cancer Res 2008, 14(11):3306-3311. 10.1158/1078-0432.CCR-07-4749, 18519757.
12. Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, Andreopoulou E, Hall CS, Lodhi A, Jackson S, et al. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer 2010, 116(14):3330-3337. 10.1002/cncr.25145, 20564098.
13. Sloane JP, Ormerod MG, Neville AM. Potential pathological application of immunocytochemical methods to the detection of micrometastases. Cancer Res 1980, 40(8 Pt 2):3079-3082.
14. Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 1999, 354(9174):197-202. 10.1016/S0140-6736(98)10175-7, 10421301.
15. Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C, Schindlbeck C, Wallwiener D, Borgen E, Naume B, et al. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 107, 107(5):885-892.
16. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25(33):5287-5312. 10.1200/JCO.2007.14.2364, 17954709.
17. Krag DN, Kusminsky R, Manna E, Ambaye A, Weaver DL, Harlow SP, Covelli M, Stanley MA, McCahill L, Ittleman F, et al. The detection of isolated tumor cells in bone marrow comparing bright-field immunocytochemistry and multicolor immunofluorescence. Ann Surg Oncol 2005, 12(9):753-760. 10.1245/ASO.2005.12.004, 16079954.
18. Borgen E, Beiske K, Trachsel S, Nesland JM, Kvalheim G, Herstad TK, Schlichting E, Qvist H, Naume B. Immunocytochemical detection of isolated epithelial cells in bone marrow: non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase. J Pathol 1998, 185(4):427-434. 10.1002/(SICI)1096-9896(199808)185:4<427::AID-PATH127>3.0.CO;2-7, 9828843.
19. Borgen E, Naume B, Nesland JM, Kvalheim G, Beiske K, Fodstad O, Diel I, Solomayer EF, Theocharous P, Coombes RC, et al. Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1999, 1(5):377-388. 10.1080/0032472031000141283, 20426539.
20. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000, 342(8):525-533. 10.1056/NEJM200002243420801, 10684910.
21. Wiedswang G, Borgen E, Karesen R, Kvalheim G, Nesland JM, Qvist H, Schlichting E, Sauer T, Janbu J, Harbitz T, et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 2003, 21(18):3469-3478. 10.1200/JCO.2003.02.009, 12972522.
22. Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, Reintgen DS, Morrow M, Leitch AM, Hunt KK, McCall LM, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA 2011, 306(4):385-393. 10.1001/jama.2011.1034, 21791687.
23. Molloy TJ, Bosma AJ, Baumbusch LO, Synnestvedt M, Borgen E, Russnes HG, Schlichting E, van't Veer LJ, Naume B. The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients. Breast Cancer Res 2011, 13(3):R61. 10.1186/bcr2898, 3218950, 21672237.
24. Sola M, Margeli M, Castella E, Julian JF, Rull M, Gubern JM, Mariscal A, Barnadas A, Fraile M. Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: a prospective observational study. BMC Cancer 2011, 11:252. 10.1186/1471-2407-11-252, 3141772, 21679400.
25. Janni W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Juckstock J, Borgen E, Rack B, Braun S, Sommer H, et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis. Clin Cancer Res 2011, 17(9):2967-2976. 10.1158/1078-0432.CCR-10-2515, 21415211.
26. Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjaerde OC, Stromberg M, Wiedswang G, Kvalheim G, Karesen R, et al. Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol Oncol 2007, 1(2):160-171. 10.1016/j.molonc.2007.03.004, 19383292.
27. Farmen RK, Nordgard O, Gilje B, Shammas FV, Kvaloy JT, Oltedal S, Heikkila R. Bone marrow cytokeratin 19 mRNA level is an independent predictor of relapse-free survival in operable breast cancer patients. Breast Cancer Res Treat 2008, 108(2):251-258. 10.1007/s10549-007-9592-x, 17492378.
28. Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009, 9(4):302-312. 10.1038/nrc2627, 19308069.
29. Krag DN, Kusminsky R, Manna E, Weaver D, Harlow SP, Covelli M, Stanley MA, McCahill L, Ittleman F, Leavitt B, et al. Cytokeratin-positive cells in the bone marrow of breast cancer patients and noncancer donors. Appl Immunohistochem Mol Morphol 2009, 17(5):403-408. 10.1097/PAI.0b013e31819f4d6b, 2836413, 19417625.
30. Braun S, Auer D, Marth C. The prognostic impact of bone marrow micrometastases in women with breast cancer. Cancer Invest 2009, 27(6):598-603. 10.1080/07357900802574496, 19557580.
31. Effenberger KE, Borgen E, Eulenburg CZ, Bartkowiak K, Grosser A, Synnestvedt M, Kaaresen R, Brandt B, Nesland JM, Pantel K, et al. Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern. Breast Cancer Res Treat 2011, 125(3):729-738. 10.1007/s10549-010-0911-2, 20449649.